Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4836202 | 1.00 | MAPK14 (0.62) | MAPK14POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4840568 | 0.92 | MAPK14 (0.62) | MAPK14NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4840563 | 0.92 | MAPK14 (0.62) | MAPK14NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4836088 | 0.92 | MAPK14 (0.69) | MAPK14SMN1; SMN2MAPTTHRB | |
| SCHEMBL4836095 | 0.92 | MAPK14 (0.69) | MAPK14SMN1; SMN2MAPTTHRB | |
| SCHEMBL4838184 | 0.92 | MAPK14 (0.73) | MAPK14SMN1; SMN2 | |
| SCHEMBL4838172 | 0.92 | MAPK14 (0.73) | MAPK14SMN1; SMN2 | |
| SCHEMBL4837947 | 0.91 | MAPK14 (0.62) | MAPK14NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4837956 | 0.91 | MAPK14 (0.62) | MAPK14NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4828792 | 0.90 | MAPK14 (0.66) | MAPK14POLBNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402589-B2 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-07-22 | — | — | US | claimed |
| US-20050245555-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-03 | — | — | US | claimed |
| US-7402589-B2 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-07-22 | — | — | US | disclosed |
| US-20050245555-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245555-A1 | Tri-substituted ureas as cytokine inhibitors | IL1B, IL1A, IL6 | MAPK14 2674/4885POLB 2558/4885NPC1 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.